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Abstract
Soluble Epoxide Hydrolase (sEH) is a key enzyme in the metabolism and termination of action of epoxyeicosatrienoic acids,
derivatives of arachidonic acid, which are protective against ischemic stroke. Mice lacking sEH globally are protected from
injury following stroke; however, little is known about the role of endothelial sEH in brain ischemia. We generated
transgenic mice with endothelial-specific expression of human sEH (Tie2-hsEH), and assessed the effect of transgenic
overexpression of endothelial sEH on endothelium-dependent vascular reactivity and ischemic injury following middle
cerebral artery occlusion (MCAO). Compared to wild-type, male Tie2-hsEH mice exhibited impaired vasodilation in response
to stimulation with 1 mM acetylcholine as assessed by laser-Doppler perfusion monitoring in an in-vivo cranial window
preparation. No difference in infarct size was observed between wild-type and Tie2-hsEH male mice. In females, however,
Tie2-hsEH mice sustained larger infarcts in striatum, but not cortex, compared to wild-type mice. Sex difference in ischemic
injury was maintained in the cortex of Tie2-hsEH mice. In the striatum, expression of Tie2-hsEH resulted in a sex difference,
with larger infarct in females than males. These findings demonstrate that transgenic expression of sEH in endothelium
results in impaired endothelium-dependent vasodilation in the cerebral circulation, and that females are more susceptible
to enhanced ischemic damage as a result of increased endothelial sEH than males, especially in end-arteriolar striatal region.
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Introduction
Epoxyeicosatrienoic acids (EETs) produced in brain play an
important role in cerebral blood flow regulation [1]. They are
protective against ischemic stroke in vivo and against ischemia-
induced cell death in vitro in multiple brain- derived cell types
including neurons, astrocytes and endothelial cells [2,3,4,5]. The
actions of EETs are predominantly terminated by the enzyme
soluble epoxide hydrolase (sEH) which metabolizes EETs to
dihydroxyeicosatrienoic acids (DHETs) [6]. sEH is widely
expressed in brain including in the cerebral vasculature [4,7,8].
Stroke is a major cause of morbidity and mortality worldwide,
with lower incidence in premenopausal women compared to men
of the same age. However, the risk of stroke in women greatly
increases following menopause [9,10]. This gender difference has
therefore been attributed largely to sex hormones, with estrogen in
particular affording protection to premenopausal females [11,12].
Although the mechanism of is not fully understood, and involves
many factors and signaling pathways, studies have indicated that
sEH is involved in this sexual dimorphism. Soluble epoxide
hydrolase is expressed at higher levels in male mice, with higher
sEH protein levels in male brains compared to female and also
higher EPHX2 transcript levels (gene encoding sEH) in endothe-
lial cells cultured from male brains compared to female [3,7]. It
has been shown that female mice sustain smaller infarct sizes
following middle cerebral artery occlusion (MCAO) compared to
males; a sex difference which is abolished upon genetic knock-
down of sEH. Also, upon ovariectomy of wild-type female mice
infarct volumes increase to male levels, however ovariectomized
females with genetic ablation of sEH no longer exhibit increased
infarct volumes, indicating that ovarian sex hormones contribute
to the protection observed in the intact female mice, presumably
by decreasing sEH levels [7].
We have shown previously that sEH deletion is protective
against ischemic injury in vivo, and also that increased sEH
activity is detrimental to neurons in vitro following oxygen-glucose
deprivation (OGD) [7,13]. Much work has focused on the brain as
a whole; the function of sEH in the vascular endothelium in vivo
has not been investigated. We have demonstrated a role for sEH in
vascular responses controlling blood flow in ischemic brain [7,14].
These studies however, were carried out using sEH knockout mice,
where sEH was absent in every cell type; the effect of manipulating
sEH solely in the endothelium and the endothelial sEH specifically
in ischemic brain has not been studied. In the current study we
tested the hypothesis that endothelial sEH plays an important role
in regulating cerebral blood flow and thus influences the extent of
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ischemic injury in the brain following stroke. We also hypothesized
that since sEH levels in females are low, forced expression of the
human sEH transgene would increase their susceptibility to
ischemic insult and abolish the observed sex difference in infarct
volumes. To test this we measured endothelium- dependent
vasodilation and ischemic injury following MCAO in mice with




The investigation conformed to the Association for Assessment
and Accreditation of Laboratory Animal Care AAALAC Accred-
itation (approved November 2010) and the Office of Laboratory
Animal Welfare (LOAW Assurance # A3304-01, approved
March 2009). The Oregon Health and Science University Animal
Care and Use Committee approved all experiments
Animals
Transgenic mice expressing Tie2- driven human sEH in
endothelial cells on a C57BL/6 genetic background (Tie2-hsEH)
have been recently described [15]. Wild type (WT) littermates
were used as controls. The study was conducted in accordance
with the National Institutes of Health guidelines for the care and
use of animals in research, and protocols were approved by the
Animal Care and Use Committee of Oregon Health and Science
University (Portland, OR, USA).
Middle Cerebral Artery Occlusion (MCAO)
Mice were subjected to transient focal cerebral ischemia by use
of the intraluminal MCAO technique [16]. Briefly, 6-month old
WT and Tie2-hsEH mice were anesthetized with isoflurane (1.5–
2%) and kept warm using water pads. A transcranial laser-Doppler
probe (MBF3D, Moor Instruments, Oxford, UK) was secured on
the right temporal side of the head to monitor cerebrocortical
perfusion and verify vascular occlusion and reperfusion. A silicone-
coated 6–0 nylon monofilament was advanced into the right
internal carotid artery via the external carotid artery until laser-
Doppler signal dropped to below 30% of baseline. The animal was
maintained anesthetized with 1% isoflurane on the surgical station
for 60 minutes of occlusion. At the end of occlusion, the filament
was withdrawn for reperfusion and the mice were allowed to
recover.
Assessment of Infarct Size
Infarct size was measured 24 hours following MCAO in 2 mm
thick coronal sections using 2,3,5-triphenyltetrazolium chloride
(TTC) staining. Sections were incubated for 15 minutes in 1.2%
TTC in saline at 37uC and fixed in formalin for 24 hours. Sections
(5 per animal) were imaged, infarcted (unstained) and viable tissue
(stained) areas were measured using MCID software (InterFocus)
and integrated across all 5 sections. To discount the influence of
edema, infarct size was calculated indirectly by subtracting the
uninjured area in the ipsilateral hemisphere from the contralateral
hemisphere, then expressing infarct volume as a percentage of the
contralateral hemisphere.
Cranial Window
Anesthesia was induced as above. The head of the mouse was
secured in a stereotaxic apparatus with 2% isoflurane in oxygen-
enriched air by face mask. The scalp and connective tissue over
the parietal cranial bone were removed. Rectal temperature was
maintained at 36+/20.5uC by water pad. An area with 1 mm
diameter, 2 mm posterior and 2.5 mm lateral to Bregma, was
marked for monitoring by laser-Doppler. A small drill hole was
made superior (medial) to the laser-Doppler probe site to expose
the dura. The dura was pierced with care not to damage the
epidural or pial vessels. A 33-gauge needle connected to a
microperfusion pump with PE10 tubing was advanced 1 mm
subdurally in a lateral direction (inflow). Another drill hole was
made inferior (lateral) to the probe site, and the dura was incised
for passive drainage of the superfused fluid (ouflow). Cerebrovas-
cular cortical perfusion was monitored using a laser-Doppler flow
probe with a tip diameter of 1 mm (Moor Instruments, Oxford,
UK). The probe was placed in a location over the thinned skull
that was devoid of large visible blood vessels. The probe position
was kept fixed for the entire experiment, and background lighting
was minimized and kept constant. For experiments investigating
cortical blood flow in response to the endothelium- dependent
dilator acetylcholine, subdural superfusion with artificial cerebro-
spinal fluid (CSF) started 5 minutes after completion of surgery
and continued for 20 minutes at a constant rate of 3 ml/min.
Following CSF perfusion acetylcholine (1 mM) was superfused for
90 minutes. Artificial CSF and acetylcholine were prepared daily
and the solution was pre-warmed to 37uC.
Immunohistochemistry
Wild-type (WT) and transgenic mouse tissues were prepared
and stained as described previously [17]. Briefly, whole brain
tissues were fixed in 10% neutral buffered formalin and embedded
in paraffin, and serial sections were immunohistochemically
labeled with anti-human sEH (1:4000 dilution; a generous gift
from Dr. Bruce Hammock, University of California, Davis, CA,
USA). Sections were incubated with donkey anti-rabbit secondary
antibody (1:500 dilution; Vector Laboratories, Burlingame, CA,
USA) and visualized using liquid 3,3-diaminobenzidine solution
(Dako, Carpinteria, CA, USA). Slides were counterstained with
Harris hematoxylin (Harelco, Gibbston, NJ, USA), and image
capture using ImageScope software (Aperio Technologies, Vista,
CA, USA) was performed as described by the supplier.
Real-Time Quantitative PCR
Expression of human sEH in mouse brain was confirmed after
RNA purification of brain tissue with the RNAeasy Mini kit
(Qiagen, Valencia, CA, USA), conversion to cDNA with High
Capacity cDNA Archive kit, (Applied Biosystems, Foster City, CA,
USA) and real-time PCR using TaqMan probes to murine
GAPDH (Mm 99999915_g1) and human EPHX2 (Hs
00157403_m1) (Applied Biosystems).
LC-MS/MS
Plasma DHET levels were determined by liquid chromatogra-
phy, tandem mass spectroscopy (LC/MS/MS) as described
previously [17]. Perfusates were pooled, spiked with 30 ng
PGE2-d4, 10,11- DiHN, and 10,11-EpHep (Cayman) as internal
standards, mixed with 0.1 vol of 1% acetic acid in 50% methanol,
and extracted by serial passage through Oasis HLB C18 3 ml
columns (Waters, Milford, MA, USA). Columns were washed
twice with 0.1% acetic acid in 5% methanol, and eluted with
methanol into glass tubes containing 6 ml of 30% glycerol in
methanol. The methanol was evaporated under a stream of
nitrogen gas, and the dried tubes were frozen and stored at 280uC
until analysis. Online liquid chromatography of extracted samples
was performed with an Agilent 1200 Series capillary HPLC
(Agilent Technologies, Santa Clara, CA, USA). Separations were
achieved using a Phenomenex Luna C18(2) column (5 mm,
150 x1 mm; Phenomenex, Torrance, CA, USA), which was held
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at 40uC. Mobile phase A was 85:15:0.1 water:acetonitrile:acetic
acid. Mobile phase B was 70:30:0.1 acetonitrile:methanol:acetic
acid. Gradient elution was used; mobile phase percentage B and
flow rate were varied as follows: 0% B at 87.5 ml/min at 0 min,
ramp from 0 to 2 min to 25% B at 87.5 ml/min, ramp from 2 to
5 min to 50% B at 60 ml/min, ramp from 5 to 23 min to 92.5% B
at 60 ml/min, ramp from 23 to 23.5 min to 100% B at 87.5 ml/
min, hold from 23.5 to 29 min at 100% B, ramp from 29 to
29.6 min down to 0% B, and hold 0% B to 33 min. Samples were
solvated in 100 ml of 40% ethanol. The injection volume was
20 ml. Samples were analyzed in triplicate. Negative ion electro-
spray ionization tandem mass spectrometry was used for detection.
Analyses were performed on an MDS Sciex API 3000 equipped
with a TurboIonSpray source (Applied Biosystems). Turbo
desolvation gas was heated to 275uC at a flow rate of 5.75 L/min.
Statistical Analysis
Differences between two groups were evaluated with a t-test,
while a 2-way ANOVA with post hoc Holm Sidak test was used
for comparisons between multiple groups. The criterion for
statistical significance was set at P,0.05. All values are reported
as mean +/2S.E.M.
Results
Mice carrying the Tie2-hsEH transgene expressed human sEH
transcript and protein in the brain (Figure 1A and B).
Immunolabeling was observed in, and confined to, both large
and small vessels, with dense labeling in the vascular endothelium
(Figure 1A). Immunolabeling was not observed in any other cell
type. These mice displayed increased plasma levels of the EETs
hydrolysis products, DHETs, as measured by LC-MS/MS. 14,15-
DHETs were increased from 168.68 pg/ml in WT to 317.07 pg/
ml in Tie2-hsEH expressing mice and 11,12-DHETs were
increased from 99.94 pg/ml to 164.94 pg/ml, respectively
(Figure 1D) (n = 8 WT, n = 13 Tie2-hsEH, P,0.05). Medium
collected from aortic endothelial cell cultures from Tie2-hsEH
mice also had lower arachidonic acid and linoleic acid epox-
ide:diol ratios (14,15-EET:DHET and 12,13-EpOME:DiHOME)
as measured by LC-MS/MS, both of which serve as readouts of
increased sEH function (Figure 1D) (n = 3, P,0.05).
Endothelium- dependent vasodilation was impaired in mice
carrying the Tie2-hsEH transgene compared to wild-type controls
(Figure 2). Cortical blood flow in male mice in response to 1 mM
acetylcholine (ACh) was measured by laser-Doppler through a
cranial window (Figure 2C). Figure 2A shows representative traces
of laser-Doppler perfusion in both genotypes, at baseline and in
the 90 minutes following ACh administration. Blood flow was
significantly reduced in Tie2-hsEH compared to wild-type mice,
with 58.9% (+/224.3%) increase in blood flow from baseline on
stimulation with ACh compared to 105.3% (+/226%) respectively
(Figure 2B) (n = 9 WT, n = 8 Tie2-hsEH, P,0.05).
Since increased endothelial expression of sEH impaired ACh-
stimulated vasodilation at baseline, we next investigated whether
this endothelial dysfunction is deleterious following MCAO in
Tie2-hsEH compared to WT mice. Male mice were subjected to
60 minutes of MCAO and infarct volume was assessed following
24 hours of reperfusion. Infarct volume was assessed histologically
by TTC labeling (Figure 3C). In male mice, no difference in
infarct size was observed in either cortex (Figure 3A), caudate
putamen (striatum; Figure 3B) or the whole hemisphere (not
shown) between Tie2-hsEH and WT mice (Figure 3B) (n = 5,
P.0.05).
Sex differences have been reported in sEH expression; females
express lower levels of sEH in the brain affording them protection
from ischemic insult [7]. We therefore hypothesized that
increasing levels of sEH in female endothelium would render
them more susceptible to ischemic damage. Female mice were
subjected to 60 minutes of MCAO, followed by 24 hours of
reperfusion. Brains were analyzed by TTC labeling, Figure 3C
shows representative images of sections from WT and Tie2-hsEH
mouse brains depicting smaller infarct area (white) in WT
compared to Tie2-hsEH brain. On quantification, infarct volume
was significantly larger in the caudate putamen (striatum) of Tie2-
hsEH mice compared to their WT counterparts (67.78+/24.52%
compared to 44.34+/25.40% respectively; n = 7 WT, n = 10
Tie2-hsEH, P,0.05, Figure 3B). There was however no difference
in the cortex (Figure 3A) or whole hemisphere (not shown)
between the Tie2-hsEH and WT mice. There was however a sex
difference in infarct volume in the WT cortex (Figure 3A), in
which females sustained smaller infarcts compared to males
(35.23+/23.26% compared to 44.34+/23.85% respectively;
n = 7 female, n = 5 male, P,0.05); this difference persisted in the
Tie2-hsEH mice (32.77+/22.78% female, 43.12+/23.85% male;
n = 10 female, n = 5 male, P,0.05). In the striatum, while there
was no significant sex difference in infarct size in the WT mice, a
sex difference was revealed in mice over-expressing hsEH, with
females exhibiting larger infarct volumes than males (67.78+/
24.52% compared to 45.14+/26.39% respectively; n = 10
female, n = 5 male, P,0.05). To ensure that the insult sustained
was comparable between groups and that this observed difference
is not due to varying levels of occlusion, cerebral blood flow was
measured during and immediately after MCAO (Figure 4); no
difference in blood flow was observed during the MCAO
procedure.
Discussion
We report the following new findings: (1) Endothelial over-
expression of sEH impairs ACh- induced increase in cerebral
blood flow in males. (2) Endothelial over-expression of sEH does
not exacerbate ischemic damage following MCAO in males,
however (3) females are susceptible to increased ischemic damage
following MCAO due to increased sEH expression in brain
endothelium, especially in end-arteriolar striatal region. (4) In the
cortex, endothelial over-expression of sEH does not impact the
observed sex difference in infarct size following MCAO, however
(5) in the striatum while there is no sex difference in wild type
mice, endothelial over-expression of sEH renders females more
susceptible to ischemic damage than males.
We have previously demonstrated a role for sEH in mediating
vascular function. EETs are known vasodilators; it would follow
that knocking out sEH, which hydrolyzes EETs would increase
their concentration. Mice with global deletion of the sEH gene
display higher cerebral blood flow levels during MCAO compared
to WT controls [14]. The current study demonstrates the reverse
effect on cerebral blood flow regulation; male mice expressing
higher levels of endothelial sEH display an impaired vasodilator
response to stimulation with ACh. In addition to causing the
release of nitric oxide (NO), ACh is known to release endothelial
EETs in the cardiac circulation [18]. Thus, ACh stimulation
causes release of EETs, resulting in vasodilation; with increased
sEH present in our mouse model, this should increase the
hydrolysis product of EETs, which is indeed what we found. These
mice have higher circulating blood levels of 14,15- and 11,12-
DHET as well as a lower ratio of 14,15- EET:DHET released by
endothelial cells, confirming recent studies which have also shown
Endothelial sEH in Cerebrovascular Function
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e61244
Figure 1. Characterization of Tie2-hsEH mice. A. Schematic of the Tie2-hsEH transgenic construct used to generate mice used in this study. B.
Sections of WT (left) and Tie2-hsEH (right) mouse brains immunolabeled for human sEH showing sEH in capillaries and large vessels in Tie2-hsEH.
Inserts, blood vessels in cross section, show intense labeling in vascular endothelium in Tie-hsEH. C. Real-time PCR analysis of human sEH levels in
brain tissue, showing presence of transgene expression in Tie2-hsEH and none in WT mice. D. LC-MS/MS analysis showing significantly increased
14,15- and 11,12- DHET plasma levels in Tie2-hsEH mice compared to WT (n = 8 WT, n = 13 Tie2-hsEH, P,0.05). E. LC-MS analysis of culture medium
from WT and Tie2-hsEH aortic endothelial cells showing decreased ratios of 12,13-EpOME:DiHOME and 14,15-EET:DHET released by Tie2-hsEH
endothelial cells compared to WT (n = 3 both groups, P,0.05).
doi:10.1371/journal.pone.0061244.g001
Figure 2. Effect of sEH over-expression on endothelium-dependent cerebral blood flow in male mice. A. Representative traces
illustrating reduced LDP response to 1 mM ACh stimulation in Tie2-hsEH compared to WT mice over time. B. Quantification of laser Doppler perfusion
(LDP) shows that perfusion is significantly reduced in Tie2-hsEH mice compared to WT. (n = 9 WT, n = 8 Tie2-hsEH, P,0.05). C. Schematic
representation of cranial window preparation.
doi:10.1371/journal.pone.0061244.g002
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reduced epoxide:diol ratios and decreased 14,15-EET in plasma
and endothelial cells of other tissues from mice expressing this
human sEH transgene [15,19]. This therefore presumably leads to
lower levels of bioavailable EETs, and thus a reduced vasodilator
response to ACh.
Endothelial response to acetylcholine has been used as a
benchmark for measuring endothelial dysfunction [20,21]. It has
been suggested that sEH contributes to endothelial dysfunction;
indeed inhibition of sEH ameliorates endothelial dysfunction in
mouse models of diabetes and hypertension [22]. This current
study adds further substance to this notion; we show that
increasing sEH levels in endothelial cells leads to impaired ACh-
vascular responses in male mice, and thus endothelial dysfunction.
Male mice expressing the Tie2-hsEH transgene did not exhibit
larger infarct sizes following MCAO. Although perhaps surprising,
this can be explained by the fact that sEH is already highly
expressed in males, and therefore higher levels may not be
deleterious in terms of ischemic injury [7]. Interestingly, over-
expression of sEH in the endothelium also had no adverse effects
on infarct size in the heart [15].
As discussed earlier, sEH expression in the brain is sexually
dimorphic. In whole brain extracts, males exhibit higher protein
levels than females; this is reflected in higher 14,15-DHET levels
in males than females [7]. In vitro, we have also shown that male
endothelial cells are more susceptible to death following oxygen-
glucose deprivation than females; a phenomenon attributable to
higher expression of sEH in males than females, resulting in higher
EETs levels in females than males [3]. In this study, possession of
the Tie2-hsEH transgene altered response to injury in females, but
not males. Increased sEH expression had a deleterious effect on
infarct size following MCAO in females only in the caudate
putamen (striatum), but not in the cerebral cortex. This is
consistent with the idea that striatum is an end-arteriolar region
devoid of collaterals, unlike the cerebral cortex which is rich in
collateral vascular networks, and is therefore less dependent on
vascular mechanisms. In terms of direct comparison of the sexual
dimorphic response to MCAO, our data supports previous
findings that females sustain smaller cortical infarcts than males
[7]. Expression of the human sEH transgene in the endothelium
Figure 3. Effect of sEH over-expression on infarct size after MCAO in male and female mice. A. In the cortex, there is no significant
difference in infarct volume following MCAO in WT compared to Tie2-hsEH mice in either male or female mice (n = 5 male WT, n = 5 male Tie-hsEH,
n = 7 female WT, n = 10 female Tie2-hsEH, P.0.05). Infarct volume is reduced in females compared to males in both WT and Tie2-hsEH expressing
mice (P,0.05). B. In the caudate patamen (CP) there is no significant difference in infarct volume following MCAO in WT compared to Tie2-hsEH male
mice, however in females infarct volume is increased in Tie2-hsEH compared to WT control mice (P,0.05). The Tie2-hsEH female mice also have an
increased infarct volume compared to male Tie2-hsEH mice (P,0.05). C.Representative TCC- stained brain slices from WT and Tie2-hsEH mice from
male (left) and female (right) mice.
doi:10.1371/journal.pone.0061244.g003
Figure 4. Cerebral blood flow (CBF) during MCAO. No significant
differences in blood flow changes are observed between wild type and
Tie2-hsEH mice either during MCAO or immediately following MCAO.
doi:10.1371/journal.pone.0061244.g004
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did not alter this sex difference. In the striatum however, while
there was no difference between male and female infarct volume in
the wild-type mice, a sex difference was revealed in the mice
carrying the hsEH transgene, with females actually exhibiting
larger infarcts than males. A possible explanation for this is that, as
mentioned, the striatum is an end-arteriolar region lacking
collateral supply. It has been suggested that EETs are a
component of the endothelium- derived hyperpolarizing factor
(EDHF) response in small caliber vessels in the brain but not of
large vessels [23,24,25,26]. Therefore, increasing the expression of
sEH in females, which have lower endogenous expression than
male, in an area of the brain dependent on blood supply from
small caliber vessels will have a more profound effect than in the
males or than in the cortex.
It is important to note that this study explores the effect of
genetic manipulation of sEH specifically in the endothelium,
however the effects are still within the context of the whole brain.
Other cell types within the brain, including perivascular astrocytes
and neurons have been shown to produce both EETs and sEH. In
the human brain, sEH is expressed throughout the brain in
neurons, oligodendrocytes, astrocytes, endothelial cells and also
smooth muscle cells of arterioles [8]. Studies have shown that
astrocyte- derived EETs are involved in neurovascular coupling
and vasodilation [4,27], and perivascular nerve- derived EETs
mediate neurogenic vasodilation of the cerebral vasculature [28].
Therefore although in the current study we are investigating the
effects of increasing sEH expression in endothelial cells specifically,
the results observed here may be dampened, or compensated for,
by vasodilation induced by EETs generated by other cell types
within the brain, as it is likely that EETs derived from multiple
sources act in concert to exert their protective role.
In summary, the current study demonstrates a role for
endothelial sEH in the regulation of cerebral blood flow. We also
confirm the sexual dimorphism observed in endothelial sEH
function, with increased sEH expression being detrimental to
females but not males in terms of infarct size following MCAO.
These findings suggest that endothelial sEH is a key regulator of
cerebrovascular endothelial function and an important contributor
to the sexually dimorphic response to cerebral ischemic injury.
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